Skip to main content

Table 7 Treatment outcomes of FP vs. GP

From: Gemcitabine-based versusfluoropyrimidine-based chemotherapy with or without platinum in unresectable biliary tract cancer: a retrospective study

  FP GP P value
Number of patients 83 94  
RR (%) 24.3 17.6 0.310
DCR (%) 67.6 54.8 0.103
PFS (months) 4.6 (95% CI, 3.5–5.7) 4.3 (95% CI, 3.6–5.0) 0.787
OS (months) 8.1 (95% CI, 7.0–9.3) 8.0 (95% CI, 6.0–10.0) 0.357
  1. F, fluoropyrimidines; P, platinum; G, gemcitabine; RR, response rate; DCR, disease control rate; PFS, progression free survival; CI, confidence interval; OS, overall survival